Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 9/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.35 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259365 | 1.00 | ACLY (0.41) | ACLYPPARAACACBACACAALOX5 | |
| SCHEMBL6205461 | 0.96 | ACLY (0.38) | ACLYPPARAACACBACACAALOX5 | |
| SCHEMBL10258915 | 0.96 | ACLY (0.38) | ACLYPPARAACACBACACAALOX5 | |
| SCHEMBL10259708 | 0.93 | ACLY (0.35) | ACLYPPARAACACBACACAALOX5 | |
| SCHEMBL5705601 | 0.93 | ACLY (0.35) | ACLYPPARAACACBACACAALOX5 | |
| SCHEMBL8745116 | 0.89 | PPARA (0.33) | ACLYPPARAACACBACACAALOX5 | |
| SCHEMBL6206764 | 0.89 | PPARA (0.33) | ACLYPPARAACACBACACA | |
| SCHEMBL12056031 | 0.89 | PPARA (0.33) | ACLYPPARAACACBACACA | |
| SCHEMBL10257083 | 0.87 | PPARA (0.37) | ACLYPPARAALOX5PTGS2GLS2 | |
| SCHEMBL3279833 | 0.87 | ACLY (0.42) | ACLYPPARAACACBACACAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | claimed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | ACLY 358/4885PPARA 27/4885ACACB 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.